Compare Gigacloud Technology Inc (GCT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Tango Therapeutics Inc. — how do they compare? Gigacloud Technology Inc trades at $57.53 (market cap $2.06B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Tango Therapeutics Inc. for 0 Days on average.
| GCT | TNGX | |
|---|---|---|
Market Cap | $2.06B | $3.74B |
Volume | 820,423 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $57.75 | $32.90 |
52-Week Low | $25.46 | $7.50 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.19B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% today, with a bullish technical outlook from moving averages but bearish oscillators. The company demonstrates strong fundamentals with consistent earnings beats, 10.65% net margins, and robust 32.34% ROE. Recent news highlights institutional interest and analyst optimism despite insider selling activity. Revenue growth continues with 2026 projections showing $1.5B revenue and maintained profitability.
GCT presents a compelling investment case with attractive valuation multiples (P/E 13.58) and strong execution, though technical indicators show overbought conditions. Key risks include market volatility and competitive pressures, but analyst consensus remains bullish with 66.7% buy ratings and $32.50 price target suggesting significant upside potential from current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
